209 related articles for article (PubMed ID: 27729803)
1. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
Abedin SM; Boddy CS; Munshi HG
Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
[TBL] [Abstract][Full Text] [Related]
2. Targeting BET bromodomain proteins in solid tumors.
Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
Wadhwa E; Nicolaides T
Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
[TBL] [Abstract][Full Text] [Related]
5. [Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].
Gao RL; Zeng CW; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1365-1368. PubMed ID: 34362532
[TBL] [Abstract][Full Text] [Related]
6. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations.
Ma T; Chen Y; Yi ZG; Li YH; Bai J; Li LJ; Zhang LS
Genes Dis; 2023 Nov; 10(6):2306-2319. PubMed ID: 37554207
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
Reyes-Garau D; Ribeiro ML; Roué G
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
Bertoni F; Stathis A
Curr Opin Hematol; 2019 Jul; 26(4):273-280. PubMed ID: 31116107
[TBL] [Abstract][Full Text] [Related]
11. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
Braun T; Gardin C
Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
[TBL] [Abstract][Full Text] [Related]
12. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
13. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain inhibitors: what does the future hold?
Bhattacharya S; Piya S; Borthakur G
Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
[TBL] [Abstract][Full Text] [Related]
15. BET Proteins as Targets for Anticancer Treatment.
Stathis A; Bertoni F
Cancer Discov; 2018 Jan; 8(1):24-36. PubMed ID: 29263030
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.
Halder TG; Soldi R; Sharma S
Curr Opin Oncol; 2021 Sep; 33(5):526-531. PubMed ID: 34280171
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials.
Sun Y; Han J; Wang Z; Li X; Sun Y; Hu Z
Front Pharmacol; 2020; 11():621093. PubMed ID: 33574760
[No Abstract] [Full Text] [Related]
18. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibitors in leukemia.
Basheer F; Huntly BJ
Exp Hematol; 2015 Aug; 43(8):718-31. PubMed ID: 26163798
[TBL] [Abstract][Full Text] [Related]
20. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
